Mylan Recalls Methotrexate Injection (USP 50mg/2mL) Due To Particulate Matter

Mylan Pharmaceuticals ULC, in consultation with Health Canada, is voluntarily recalling one lot of Methotrexate Injection USP 50 mg/2 mL due to the potential presence of foreign particulate matter. At this time, no other lots of this product have been distributed by Mylan. Methotrexate Injection is administered by healthcare professionals but Health Canada is also aware that this product may be self-administered by subcutaneous injection (under the skin) by patients at home. The risks associated with subcutaneous injection of foreign particulate matter include local reaction at the injection site and/or swelling or possible allergic reaction and infection.

Speak to your healthcare practitioner if you have concerns about your health. Consult with your healthcare practitioner about stopping the use of this product and getting a replacement medication in order to complete your scheduled therapy. Report any adverse events to Health Canada.